Dr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical Officer
May 24 2023 - 8:30AM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products and devices for patients with endocrine and
orphan lung diseases, announced Burkhard Blank, MD, has joined the
company as Executive Vice President, Research & Development and
Chief Medical Officer, effective today. Blank will report directly
to Michael Castagna, PharmD, Chief Executive Officer, and will
serve on the company’s executive leadership team.
“Burkhard is an accomplished R&D leader and CMO whose
experience will be beneficial as we continue to drive our pipeline
and future growth,” said Dr. Castagna. “Burkhard will assume
consolidated responsibility for our R&D, regulatory and medical
groups, as we pursue our goal of one new indication or product
launch per year between 2025-2030.”
Dr. Blank brings to MannKind more than 25 years of broad
managerial experience and global drug development across all
clinical, medical, and regulatory disciplines in multiple diseases
areas. He has deep knowledge in the inhaled therapeutics space and
has been instrumental in eight NDA and MAA submissions for small
molecules, biologics, and drug-device combinations. Dr. Blank
recently served as CMO/Head of R&D at Pharnext SA after serving
seven years in the same position at Acorda Therapeutics. While at
Acorda, he oversaw the Phase 3 development in North America and in
Europe for Inbrija® (levodopa inhalation powder) for Parkinson’s
disease with subsequent one-cycle approvals by the FDA and the
EMA.
Earlier in his career, Dr. Blank spent 20 years between
Boehringer Ingelheim Pharmaceuticals in Ridgefield, CT,
and Boehringer Ingelheim GmbH in Germany, serving in
progressive leadership roles. Under his guidance, four products
received approval including Spiriva® (for COPD) for which he
oversaw development and led the presentation at the FDA advisory
committee meeting. He has proven success in large and small
organizations and will be based in Danbury. He received his medical
degree from Universitaet Marburg, Germany, and is board-certified
in internal medicine.
“I’m excited by MannKind’s burgeoning pipeline with the
potential to address serious unmet needs for those living with
nontuberculous mycobacterial lung disease (NTM), idiopathic
pulmonary fibrosis (IPF) and diabetes,” said Dr. Blank. “The
talented team at MannKind has already made impressive progress
advancing the pipeline and I am looking forward to building on that
momentum with them.”
About MannKindMannKind Corporation (Nasdaq:
MNKD) focuses on the development and commercialization of
innovative therapeutic products and devices to address serious
unmet medical needs for those living with endocrine and orphan lung
diseases.
We are committed to using our formulation capabilities and
device engineering prowess to lessen the burden of diseases such as
diabetes, pulmonary arterial hypertension (PAH) and nontuberculous
mycobacterial (NTM) lung disease. Our signature technologies –
dry-powder formulations and inhalation devices – offer rapid and
convenient delivery of medicines to the deep lung where they can
exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide,
we are on a mission to give people control of their health and the
freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on
LinkedIn, Facebook, Twitter or Instagram.
Forward-Looking StatementsThis press release
contains forward-looking statements about pipeline growth plans and
potential product launches that involve risks and uncertainties.
Words such as “believes”, “anticipates”, “plans”, “expects”,
“intends”, “will”, “goal”, “potential” and similar expressions are
intended to identify forward-looking statements. These
forward-looking statements are based upon MannKind’s current
expectations. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, the risk that the products we are
commercializing may only achieve a limited degree of commercial
success, the need for product candidates to undergo nonclinical and
clinical testing and obtain regulatory approval prior to their sale
and marketing, and other risks detailed in MannKind’s filings with
the Securities and Exchange Commission, including its Annual Report
on Form 10-K for the year ended December 31, 2022, and subsequent
periodic reports on Form 10-Q and current reports on Form 8-K. You
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
All forward-looking statements are qualified in their entirety by
this cautionary statement, and MannKind undertakes no obligation to
revise or update any forward-looking statements to reflect events
or circumstances after the date of this press release.
MANNKIND is a registered trademark of MannKind Corporation.
INBRIJA is a registered trademark of Acorda Therapeutics, Inc.
SPIRIVA is a registered trademark of Boehringer Ingelheim
International GmbH.
For MannKind:
Christie Iacangelo, Corporate Communications
(818) 292-3500
Email: media@mannkindcorp.com
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jul 2024 to Aug 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2023 to Aug 2024